Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Tempus AI, Inc. Class A ( (TEM) ).
Tempus AI, a company at the forefront of AI-driven precision medicine, reported a 33% year-over-year revenue increase to $180.9 million for Q3 2024 and announced its acquisition of Ambry Genetics to enhance its genetic testing capabilities. Despite a net loss of $75.8 million, Tempus projects a full-year revenue of $700 million, reflecting a 32% growth. The acquisition aims to expand Tempus’ testing portfolio and further its strategy of using data to innovate in clinical and scientific fields, tapping into new areas like pediatrics and women’s health.
See more data about TEM stock on TipRanks’ Stock Analysis page.